Week 48 Results of EMERALD: A Phase 3, Randomized,...

Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults

Orkin, Chloe, Molina, Jean-Michel, Gallant, Joel, Negredo, Eugenia, Gathe, Joseph, Eron, Joseph, Van Landuyt, Erika, Lathouwers, Erkki, Hufkens, Veerle, Petrovic, Romana, Opsomer, Magda
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
4
Language:
english
Journal:
Open Forum Infectious Diseases
DOI:
10.1093/ofid/ofx180.009
Date:
October, 2017
File:
PDF, 272 KB
english, 2017
Conversion to is in progress
Conversion to is failed